Europe's Biotech Boom Stalls at Mid‑Stage Funding Gap, Forces Founders to Chase Capital Abroad

TL;DR: A funding shortfall between Series A and early clinical trials pushes European biotech founders to seek capital in the U.S. and Asia, slowing drug development.

Context Europe produces world‑class science, but turning discoveries into medicines requires steady cash flow. Early‑stage grants and seed money are plentiful, and later‑stage investors step in once de‑risking milestones appear. The bottleneck appears when companies need to fund IND‑enabling studies, build teams, and prepare for first‑in‑human trials—typically the Series A to early clinical phase.

Key Facts The author of a leading European biotech says he spends much of his time traveling between London, New York, San Francisco, Boston, and global investor conferences to raise capital. He notes that firms must operate globally to obtain needed funds, not because they prefer to, but because domestic sources dry up at this stage. Data shows that the average Series A round in Europe was €15 million in 2023, compared with €32 million in the United States, while late‑stage rounds above €100 million remain similar in size. The Nasdaq Biotechnology Index (NBI) rose 2.3% to 5,120 points on October 30, 2024, whereas the Euro Stoxx Biotech Index fell 1.1% to 842 points, highlighting divergent investor appetite.

What It Means Because capital is fragmented across national markets, European founders face multiple legal frameworks and investor expectations, increasing the time spent on financing rather than research. This continuity gap forces companies to rebuild syndicates at each round, slowing execution and pushing valuable intellectual property toward listings in the U.S. or Asia. The trend risks shifting long‑term value creation outside Europe unless regional funds deepen their mid‑stage pools or create cross‑border vehicles that mirror U.S. syndicate density.

Watch for upcoming EU‑level venture‑capital initiatives aimed at closing the Series A‑to‑clinical gap and for any shifts in biotech IPO activity on Euronext versus Nasdaq.